Medimi - Public Comps and Valuation Multiples

Medimi Overview

About Medimi

Medimi AB is engaged in the development, production, and marketing of medication products. It offers Medimi Pro and Medimi Smart computerized pill dispensers that are used by patients, consumers, and healthcare staff to follow their drug schedule. The company focus on the following market segments namely Pharmaceutical industry, Hospital and retirement homes, Home Health Care, Pharmacy and private care, and Connected Health (Telemedicine), E-Health and Integration in Other Systems.

Founded

HQ

Employees

Website

medimiab.com

Sectors

Metals & Mining

Financials

Last FY Revenue $0.5M

Last FY EBITDA -$1.4M

EV

$0.6M

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Medimi Financials

In the most recent fiscal year, Medimi achieved revenue of $0.5M and an EBITDA of -$1.4M.

Medimi expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Medimi valuation multiples based on analyst estimates

Medimi P&L

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$0.5M	XXX	XXX	XXX
Gross Profit	XXX	$0.1M	XXX	XXX	XXX
Gross Margin	XXX	26%	XXX	XXX	XXX
EBITDA	XXX	-$1.4M	XXX	XXX	XXX
EBITDA Margin	XXX	-277%	XXX	XXX	XXX
EBIT	XXX	-$1.3M	XXX	XXX	XXX
EBIT Margin	XXX	-256%	XXX	XXX	XXX
Net Profit	XXX	-$1.5M	XXX	XXX	XXX
Net Margin	XXX	-308%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Medimi Stock Performance

As of May 30, 2025, Medimi's stock price is SEK 0 (or $0).

Medimi has current market cap of SEK 6.6M (or $0.7M), and EV of SEK 5.9M (or $0.6M).

See Medimi trading valuation data

Medimi Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$0.6M	$0.7M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Medimi Valuation Multiples

As of May 30, 2025, Medimi has market cap of $0.7M and EV of $0.6M.

Medimi's trades at 1.2x EV/Revenue multiple, and -0.4x EV/EBITDA.

Equity research analysts estimate Medimi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medimi's P/E ratio is not available.

See valuation multiples for Medimi and 12K+ public comps

Medimi Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$0.7M	XXX	$0.7M	XXX	XXX	XXX
EV (current)	$0.6M	XXX	$0.6M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	1.2x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-0.4x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-0.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-0.4x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-0.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Medimi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Medimi Margins & Growth Rates

Medimi's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Medimi's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medimi's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Medimi and other 12K+ public comps

Medimi Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-277%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	282%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial